Table 5.
Oncological outcomes of included studies.
| Authors | n = | Follow up | Modality of outcome assessment | Tumour response to IRE | Further interventions | Survival |
|---|---|---|---|---|---|---|
| Thomson et al. 14 | 7 | 3 months | CT | 5/7 CR at 3 months 2/7 DP |
2 of 5 CR patients had one more IRE procedure | NR |
| Diehl et al. 16 | 5 | Mean 6.4 months (range 3–11) |
MRI | NR | NR | 100% OS at 3 months |
| Vroomen et al. 17 | 1 | 4 months | PET-CT | 1/1 CR at 3 months | NR | 100% OS at 4 months |
| Canvasser et al. 18 | 41 | Mean 22 months (SD 12.4) |
CT | 92% local recurrence free survival at 2 years (NB: Of 35/41 patients with sufficient follow up data) | 3/41 had RFA salvage with CR 1/41 had robotic assisted partial nephrectomy salvage with CR |
95% OS at 2 years No mortality due to RCC (NB: Of 35/41 patients with sufficient follow up data) |
| Liu, et al. 19 | 5 | Mean 22 months (range 14–31) |
Gadolinium enhanced MRI | 4/5 CR 1/5 Recurrence |
1 recurrence patient had RFA salvage with CR at 3 months | NR |
| Wendler, et al.20,21 | 7 | 27 days to nephrectomy Overall Mean 25 months (range 15–36) |
Histopathology | 4/7 CR (ypT0V0N0Pn0R0) 3/7 incomplete ablation (ypT1aV0N0Pn0R1) |
Group with nephrectomy on day 28 post-IRE for all patients | NR |
| Gul et al. 23 | 1 | 34 months | NR | 1/1 CR | NR | Alive at latest follow up of 34 months |
CR: complete response; CT: computerised tomography; DP: disease progression; IRE: irreversible electroporation; MRI: magnetic resonance imaging; NR: not reported; OS: overall survival; PET: positron emission tomography; RCC: renal cell carcinoma; RFA: radiofrequency ablation.